RZLTHealthcare · BiotechnologyThe 11 Wall Street analysts covering Rezolute, Inc. hold a median 12-month price target of $10 — +153.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 31 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Rezolute, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (78): Reported profit is backed by cash, and the company is not expanding recklessly.
Revisions (26): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on RZLT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +153.2% from it.
Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Oct 2026 | Cantor Fitzgerald | Upgrade | Overweight | — |
| 6 Oct 2026 | Citizens | Maintains | Market Outperform | $11 → $15 |
| 6 Oct 2026 | Lake Street | Maintains | Buy | $9.00 → $12 |
| 30 Sept 2026 | Lake Street | Initiates | Buy | $9.00 |
| 29 Sept 2026 | Craig-Hallum | Upgrade | Buy | $4.00 → $7.00 |
| 25 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 25 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $5.00 → $10 |
| 15 June 2026 | Guggenheim | Maintains | Buy | $6.00 → $11 |
| 15 June 2026 | Guggenheim | Maintains | Buy | — |
| 3 June 2026 | Citizens | Upgrade | Market Outperform | — |
| 3 June 2026 | Maxim Group | Maintains | Buy | — |
| 3 June 2026 | Wedbush | Maintains | Outperform | — |
| 2 June 2026 | BTIG | Maintains | Buy | — |
| 2 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2026 | Maxim Group | Maintains | Buy | — |
| 25 Mar 2026 | Wedbush | Upgrade | Outperform | — |
| 8 Jan 2026 | BTIG | Reiterates | Buy | — |
| 8 Jan 2026 | Wedbush | Maintains | Neutral | — |
| 12 Dec 2025 | Guggenheim | Maintains | Buy | — |
| 12 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
RZLT appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Rezolute, Inc. returned −59.8% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 25% of US stocks
Cheaper than 78% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 19% of US stocks
Higher than 12% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Rezolute, Inc. has a market value of $382.1M and an enterprise value of $275.2M.
Revenue in the twelve months to 31 Mar 2026: $0.0.
Net income over the same four quarters: −$81.5M.
Diluted earnings per share, trailing twelve months: $−0.82.
Free cash flow in the twelve months to 31 Mar 2026: −$73.5M.
Trailing P/E: −4.0×; forward P/E: −8.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Rezolute, Inc. employs 58 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Rezolute, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Rezolute announced that its open-label Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism is fully enrolled. Topline results are expected in mid-December 2026.
Why it matters — The enrollment milestone and expected timing of topline results provide updates on the study's progress.
Rezolute announced that the FDA has recommended holding a pre-BLA meeting, a precursor to submitting a Biologics License Application for the treatment of congenital hyperinsulinism. The Agency reiterated its commitment to addressing the unmet need in congenital and tumor-related hyperinsulinism and to serving those patient communities.
Why it matters — This signals regulatory progress toward a potential BLA submission for RZLT's congenital hyperinsulinism program.
Rezolute, Inc. reported its financial results and provided a business update for the fourth quarter and full fiscal year ended June 30, 2026. The company focuses on treating refractory hypoglycemia caused by any form of hyperinsulinism.
Why it matters — RZLT watchers would care because these fiscal year-end financial results and business update offer insight into the company's progress and financial standing as a late-stage rare disease developer.
Rezolute provided an update on the ongoing FDA review of its Phase 3 sunRIZE study data for ersodetug in congenital hyperinsulinism. The study's open-label extension phase continues with high participation and improved glycemic control indicators, while enrollment progresses in the Phase 3 upLIFT study with topline results expected before the end of 2026.
Why it matters — RZLT watchers would care because it offers an update on the FDA review timeline and encouraging early signs from the ongoing extension phase of the company's key Phase 3 program, as well as clarity on the upcoming upLIFT study results.
Rezolute, Inc., a late-stage ultra-rare disease company developing treatments for refractory hypoglycemia caused by hyperinsulinism, announced that its management will participate in upcoming investor conferences. The announcement was made via GlobeNewsWire on September 2, 2026.
Why it matters — RZLT watchers would care because management's participation in investor conferences provides opportunities for the company to communicate its progress and strategy directly to the investment community.
The 11 Wall Street analysts covering Rezolute, Inc. have a median 12-month price target of $10, with estimates ranging from $6 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering Rezolute, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rezolute, Inc. 37 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Rezolute, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (78 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +153.2% from the last close, and Ticker Nerd's factor model ranks Rezolute, Inc. 37 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Rezolute, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RZLT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $15 over the next 12 months.
Rezolute, Inc. returned -59.8% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Rezolute Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases associated with chronic glucose imbalance.
The most recent item we track (GlobeNewsWire, 14 Oct 2026): "Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism". Rezolute announced that its open-label Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism is fully enrolled. Topline results are expected in mid-December 2026.
Rezolute Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases associated with chronic glucose imbalance. Its lead program centers on ersodetug, an intravenously administered human monoclonal antibody being studied for congenital hyperinsulinism and other forms of hypoglycemia caused by hyperinsulinism. The company’s pipeline also includes additional candidates aimed at conditions such as diabetic macular edema, reflecting a broader focus on endocrine and metabolic disorders. Rezolute Inc. works at the intersection of rare disease research and targeted drug development, with its programs designed to address serious conditions that have limited treatment options. Based in Redwood City, California, the company plays a specialized role in the biopharmaceutical market by advancing therapies for ultra-rare pediatric and metabolic diseases.
CEO Mr. Nevan Charles Elam J.D. · 58 employees · United States · https://www.rezolutebio.com
